Skip to main content

An update on an incident involving one of our systems

Hide
Quest Diagnostics

The Detection of Fentanyl in Oral fluid and Urine Specimens in the North Region of the United States

SOFT 2025

Society for Forensic Toxicologists

Portland, OR, Oct 26-31, 2025

Poster presentation: The Detection of Fentanyl in Oral fluid and Urine Specimens in the North Region of the United States

Authors: Pang B, Chen L, Jenkins AJ

Medical Specialty: Prescription Drug Monitoring, Toxicology

Related content

Audio Podcast
Fentanyl: A substance of great concern
Test FAQ
Drug Testing General Toxicology Blood or Serum
On-Demand Webinar
The Growing Crisis of Novel Psychoactive Substances
Publication
Notes From the Field: Testing for Nonprescribed Fentanyl and Percentage of Positive Test Results Among Patients with Opioid Use Disorder — United States, 2019–2020
Audio Podcast
Implementing a Drug Monitoring Protocol in your practice
Audio Podcast
Novel Psychoactive Substances (NPS): A Dangerous, Widespread Public Health Issue

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only. May include AI-generated and/or AI-modified imagery.